HC Wainwright Increases Earnings Estimates for CorMedix

CorMedix Inc (NASDAQ:CRMD) – Stock analysts at HC Wainwright raised their FY2026 earnings estimates for shares of CorMedix in a report issued on Friday, August 14th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.54 per share for the year, up from their previous forecast of $0.51. The consensus estimate for CorMedix’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for CorMedix’s FY2029 earnings at $1.23 EPS and FY2030 earnings at $1.71 EPS.

CRMD has been the topic of a number of other research reports. Leerink Partners increased their price objective on shares of CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research report on Tuesday, August 11th. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Citizens Jmp reiterated a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a report on Tuesday, April 28th. Finally, Royal Bank Of Canada increased their price target on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday, August 14th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, CorMedix has a consensus rating of “Moderate Buy” and an average target price of $15.00.

CorMedix Trading Up 6.5%

CRMD opened at $8.17 on Monday. CorMedix has a 1-year low of $6.13 and a 1-year high of $14.96. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. The company has a market cap of $636.80 million, a P/E ratio of 3.82 and a beta of 1.50. The company has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $7.65.

CorMedix (NASDAQ:CRMD) last released its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. The company had revenue of $101.93 million for the quarter, compared to the consensus estimate of $96.04 million. CorMedix had a net margin of 40.49% and a return on equity of 40.52%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of CorMedix during the second quarter valued at about $49,644,000. Vanguard Group Inc. raised its holdings in shares of CorMedix by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 4,499,010 shares of the company’s stock worth $52,323,000 after acquiring an additional 521,352 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after acquiring an additional 893,518 shares during the last quarter. Deerfield Management Company L.P. bought a new position in CorMedix in the 3rd quarter valued at about $38,656,000. Finally, State Street Corp lifted its position in CorMedix by 4.6% in the 4th quarter. State Street Corp now owns 1,920,861 shares of the company’s stock valued at $22,340,000 after acquiring an additional 85,240 shares in the last quarter. 34.18% of the stock is owned by institutional investors.

CorMedix News Roundup

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Higher long-term earnings forecasts: HC Wainwright raised its FY2027 EPS estimate to $0.14 from $0.01 and its FY2028 estimate to $0.54 from $0.39. The upgrades suggest stronger expectations for CorMedix’s revenue growth and operating leverage. CorMedix FY2026 EPS Forecast Boosted by HC Wainwright
• Positive Sentiment: Price target increased: Analysts raised CorMedix’s price target to $14.00, implying substantial upside from recent trading levels and reinforcing the bullish sentiment behind the stock’s advance. CorMedix Price Target Raised to $14.00
• Positive Sentiment: FY2026 outlook improved: A separate report said HC Wainwright boosted its FY2026 EPS forecast, supporting the view that CorMedix’s commercial performance may be progressing better than previously expected. CorMedix FY2026 EPS Forecast Boosted by HC Wainwright
• Neutral Sentiment: Near-term estimates remain mixed: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.05 from a loss of $0.08, but lowered its Q4 forecast to a loss of $0.08 from a loss of $0.06. This indicates improving expectations for one quarter but continued short-term losses.
• Neutral Sentiment: 2027 is the key test: An analysis described CorMedix’s commercial foundation as durable but cautioned that 2027 will be important for proving sustained growth and profitability. CorMedix: Durable Commercial Base, But 2027 Is The Real Test

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.